http://waocp.com/journal/index.php/apjcb <p><em>The Asian Pacific Journal of Cancer Biology (APJCB) is an open access electronic journal,&nbsp;which covers all aspects related to cancer biology. </em><em>&nbsp;</em><em>The journal was launched in 2016 as the official publication of Asian Pacific Organization for Cancer Prevention (APOCP) by its west Asia Chapter (West Asia Organization for Cancer prevention -WAOCP) .&nbsp; All manuscripts published in the Asia Pacific Journal of Cancer Biology, are under the terms of the Creative Commons Attribution License. This permits anyone to copy, distribute, transmit and adapt the published work, provided the original work and source are appropriately cited.</em></p> West Asia Organization for Cancer Prevention en-US Asian Pacific Journal of Cancer Biology 2538-4635 <p><em><img src="/journal/public/site/images/admin/Creative-Common.jpg" width="146" height="51">&nbsp;</em><em>West Asia Organization for Cabcer Prevention retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License 4 (This permits anyone to copy, distribute, transmit and adapt the published work, provided the original work and source are appropriately cited).&nbsp;</em></p> http://waocp.com/journal/index.php/apjcb/article/view/1377 <p>The recent coronavirus disease 2019 outbreak and viral infections around the world has had an enormous impact on the global health burden, threatening the lives of many individuals, spatially with underlying disease like cancerous patients and has had severe socio-economic consequences. Many pharmaceutical and biotechnology companies have commenced intensive research on different therapeutic strategies, from repurposed antiviral drugs to vaccines and monoclonal antibodies to prevent the spread of the disease and treat infected patients. Among the various strategies, advanced therapeutic approaches including cell- and gene-editing-based therapeutics are also being investigated, and initial results in in-vitro and early phase I studies have been promising. However, further assessments are required. This article reviews the underlying mechanisms for the pathogenesis of, and discusses available therapeutic candidates and advanced modalities that are being evaluated and used for treatment for immune deficient patients in cancers and viruses infected.</p> Nadia Ghasemi Darestani Soheyla Hashemi Zahra Rahimi Raheleh Janghorbanian Poodeh ##submission.copyrightStatement## http://creativecommons.org/licenses/by-nc/4.0 2024-04-15 2024-04-15 9 2 257 261 10.31557/apjcb.2024.9.2.257-261